• Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effects
  • New analyses showed patients in mitapivat arm had clinically meaningful reduction in transfusion burden compared with placebo
  • Patients in mitapivat arm who achieved hemoglobin response had clinically meaningful benefits across measures of sickle cell pain crises, fatigue, and other patient-reported outcomes
  • Mitapivat was well-tolerated, with a safety profile consistent with previous trials of mitapivat in sickle cell disease
  • Company to host investor conference call and webcast today at 9:00 a.m. ET (3:00 p.m. CEST)